Skip to content
Terminus Peptides
  • Research use only — not for human or veterinary use
  • 55 compound profiles, every source cited
  • 62 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Combination

CJC-1295 and ipamorelin combination

Also known as CJC/Ipa

In vitro — evidence level 1 of 4: In-vitro evidenceExperimental — UK regulatory status: Experimental — not authorised for human use in the UK

Overview

A two-peptide mixture with no combination data, in which the identity of one component is usually unstated.

Category
Combination
Highest evidence level identified
In-vitro evidence
Last scientifically reviewed
20 August 2026
Last regulatory review
20 August 2026

Mechanism under investigation

This pairs a growth hormone-releasing hormone receptor agonist with a selective ghrelin receptor agonist, on the rationale that stimulating two distinct upstream receptors amplifies pituitary output more than either alone. The underlying physiological principle derives from studies of other molecules in those two classes, not from this pair. The combination’s net effect on pulse amplitude, IGF-1, cortisol, prolactin and glucose handling has never been characterised in humans.

Research areas

  • Pituitary endocrinology
  • Combination pharmacology

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

None for the pair.

Animal evidence

Studies in living non-human animals.

None. No animal study administers these two together.

Human observational evidence

Studies observing people without assigning an intervention.

None. No published case series, cohort or registry data on the pair.

Clinical-trial evidence

Studies assigning an intervention to human participants.

None. No registered or published controlled trial of the combination exists. A 2026 review states plainly that the stacking practice is largely driven by anecdotal rationale and that controlled clinical evidence supporting synergy or meaningful body-composition outcomes in healthy people remains limited. Every registered trial of either compound is single-agent, and neither single-agent programme succeeded: the CJC-1295 phase 2 was terminated, and the ipamorelin phase 2 did not progress to approval.

Study limitations

  • The evidence level shown is the floor of the framework and overstates the position. The combination has not been tested at any level.
  • The identity of the CJC-1295 component is usually unstated, and it matters enormously. The form carrying a drug affinity complex has a half-life of roughly six to eight days; the form without it is short-acting and has no published human pharmacokinetics at all. Two products bearing the same name may differ by orders of magnitude in duration.
  • A 2026 review records that the form most commonly used in these blends is the one without the albumin-binding modification — that is, the version with essentially no human evidence.
  • Neither constituent’s own development programme succeeded, so extrapolating a benefit for the pair means extrapolating from two discontinued single-agent programmes.
  • The sample-quality findings for directly-marketed research-grade peptides apply to both constituents.

UK regulatory context

Experimental — not authorised for human use in the UK

A compound appearing in research literature that holds no UK authorisation for human use in any indication.

Source: The Human Medicines Regulations 2012, regulation 46 — prohibition on sale or supply of an unauthorised medicinal product (opens legislation.gov.uk in a new tab) (legislation.gov.uk)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

No combination safety data exist. Effects documented for this class of peptides include overactivation of the growth hormone axis, disturbed glucose handling and insulin resistance, fluid retention and soft-tissue symptoms, joint and muscle pain, and injection-site reactions, with corticotropin and cortisol elevation prominent for the releasing-peptide class. Whether stimulating two upstream receptors concurrently amplifies these is unstudied — though amplifying the shared downstream output is the stated purpose. A 2026 review also notes such use typically occurs within broader polypharmacy, so real-world signals are confounded.

References